DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Hutchinson-Gilford progeria syndrome — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHutchinson-Gilford progeria syndrome maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hutchinson-gilford progeria syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
farnesyltransferase, CAAX box, subunit alpha (FNTA) — FNTA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet fardrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2H6F · 1.5 Å · ligand FARNESYL (FAR). Experimental structure, not a prediction.
What the evidence adds up to
Hutchinson–Gilford progeria syndrome is a genetic disorder first documented in 1886. A 2022 case report describes a three-year-old girl with a large head and eyes, receded jaws, a narrow nose, a protruded forehead, decreased eyebrows and eyelash hair, stunted growth, and severe wrinkles, giving an old face appearance. A genetic test confirmed the diagnosis. The report notes the case is presented because of the syndrome’s rarity.
A 2018 review states that the syndrome results from the accumulation of a metabolite formed during processing of the mutated pre-lamin A protein. The review’s purpose is to increase awareness and discuss new therapeutic approaches, but it provides no data on survival, response rates, or sample sizes from any trial or treatment.
No concrete numbers on survival or response rates are given in either abstract. No drug is mentioned in either abstract. The 2018 review mentions therapeutic approaches in general terms but does not name any specific drug or report any outcomes.
What is still missing are any published clinical trial results with measurable endpoints, any patient stratification by genetic mutation type, and any funding for a trial that would test a specific drug against placebo or standard care in a defined cohort.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Dermatology & Dermatologic Surgery · 2022 · 0 citations · open access
A 3-Year-Old Girl with Old Face Appearance: Case Report
AbstractHutchinson–Gilford Progeria Syndrome (HGPS) is a genetic disorder. Patients who suffer from this disorder show premature aging and a “plucked-bird” appearance on the face. This case reports a 3-year-old female, who manifested the symptoms of HGPS. The patient has a large head and eyes, receded jaws, a narrow nose, protruded forehead, decreased eyebrows and eyelash hair, stunted growth, and severe wrinkles. A genetic test was conducted to confirm the existence of the disease. The case is reported due to its rarity.
Zenodo (CERN European Organization for Nuclear Research) · 2018 · 0 citations · open access
A Brief Review On Hutchinson-Gilford Progeria Syndrome
Abstract<em>Hutchinson-Gilford Progeria Syndrome (HGPS) was first documented in 1886 in the medical literature. A HGPS patient has the physical characteristics and appearances of an elderly individual. It is now clear that the syndrome results from the accumulation of a metabolite formed during processing of the mutated pre-lamin A protein. The purpose of this review is to increase the awareness of Hutchinson-Gilford Progeria Syndrome and its conditions and discuss the new therapeutic approaches among worldwide.</em> <strong>Key words:</strong><em> Hutchinson-Gilford Progeria Syndrome, bone deformation, pre-lamin A, Progeroid syndromes.</em>
Zenodo (CERN European Organization for Nuclear Research) · 2018 · 0 citations · open access
A Brief Review On Hutchinson-Gilford Progeria Syndrome
Abstract<em>Hutchinson-Gilford Progeria Syndrome (HGPS) was first documented in 1886 in the medical literature. A HGPS patient has the physical characteristics and appearances of an elderly individual. It is now clear that the syndrome results from the accumulation of a metabolite formed during processing of the mutated pre-lamin A protein. The purpose of this review is to increase the awareness of Hutchinson-Gilford Progeria Syndrome and its conditions and discuss the new therapeutic approaches among worldwide.</em> <strong>Key words:</strong><em> Hutchinson-Gilford Progeria Syndrome, bone deformation, pre-lamin A, Progeroid syndromes.</em>
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
